Dr. Margrit Wiesendanger, MD, PhD

Dr. Wiesendanger practices at The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System.

Dr. Wiesendanger's NPI, 1922200245, was assigned on May 31, 2007. Dr. Wiesendanger graduated from Albert Einstein College of Medicine of Yeshiva University in 2000. Dr. Wiesendanger holds New York license 222037.

Dr. Wiesendanger's primary practice is The Mount Sinai Hospital, at One Gustave L Levy Place, New York, NY 10029 in New York County. The practice phone is (212) 241-7981. Dr. Wiesendanger also practices at The Mount Sinai Hospital, 1 Gustave L Levy Pl, New York, NY 10029.

Dr. Wiesendanger's primary practice is The Mount Sinai Hospital in New York, New York, part of Mount Sinai Health System. Dr. Wiesendanger is also affiliated with Mount Sinai Beth Israel. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Wiesendanger to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wiesendanger practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Wiesendanger's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Wiesendanger is licensed in New York.

CMS data shows 257 Medicare services from Dr. Wiesendanger across 2 procedure codes in 2024, all of them office visits, for 169 Medicare patients. Medicare paid $21,354 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 169 Medicare patients who saw Dr. Wiesendanger in 2024. The largest group is 65 to 74, with 64 patients. 73% of them have arthritis, and 71% have high blood pressure. 32% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wiesendanger's median patient age at 57, with 73% women.

In 2024, Dr. Wiesendanger wrote 2,307 Medicare Part D claims for 271 patients. 78% of them were for generic drugs. CMS names the drug for 2,117 of them, across 45 drugs with 11 or more claims each, at $2,054,833 in total drug cost. In 2023, CMS named 2,067 claims across 39 drugs.

Dr. Wiesendanger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Wiesendanger as offering telehealth.

Dmand AI links 2 papers to Dr. Wiesendanger, published from 2011 to 2024. Dr. Wiesendanger's most frequent co-authors are Emily A. Carroll, Percio S. Gulko and Mathew Shane Maurer, MD.

CMS Open Payments shows 9 general payments to Dr. Wiesendanger from 6 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 92% of the total. Bristol-Myers Squibb Company paid the most, $4,255.

Dr. Wiesendanger graduated from Albert Einstein College of Medicine of Yeshiva University in 2000.